Uma M. Borate
Advanced in Essential Thrombocythemia

Dr. Uma M. Borate

Hematology
Osu Internal Medicine LLC
410 W 10th Ave, 
Columbus, OH 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
17 Years of Experience
Advanced in Essential Thrombocythemia
Osu Internal Medicine LLC
410 W 10th Ave, 
Columbus, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Uma Borate is a Hematologist in Columbus, Ohio. Dr. Borate has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Essential Thrombocythemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Borate is currently accepting new patients.

Her clinical research consists of co-authoring 71 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 3 clinical trials in the study of Essential Thrombocythemia.

Specialties
Hematology
Licenses
Internal Medicine in OH
Hospital Affiliations
Ohio State University State Health System
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

OSU INTERNAL MEDICINE LLC
410 W 10th Ave, Columbus, OH 43210
Other Locations
OSU INTERNAL MEDICINE LLC
3900 Stoneridge Ln, Dublin, OH 43017

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase I Study to Evaluate Safety of Ruxolitinib in Combination With Azacitidine + Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase I Study to Evaluate Safety of Ruxolitinib in Combination With Azacitidine + Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Recruiting
Publish Date: August 29, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Ruxolitinib, Venetoclax
Study Phase: Phase 1
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Enrollment Status: Recruiting
Publish Date: September 19, 2024
Intervention Type: Drug, Biological, Other
Study Drugs: Samalizumab, BI-836858, Daunorubicin, Cytarabine, Azacitidine, AG-221, Entospletinib, Decitabine, Pevonedistat, AG-120, Gilteritinib, AZD5153, Venetoclax, TP-0903, AZD5991
Study Phase: Phase 1/Phase 2
A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome
A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome
Enrollment Status: Terminated
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drugs: MBG453 Anti-TIM3 Monoclonal Antibody, NIS793 Anti-TGFBeta Monoclonal Antibody, Canakinumab
Study Phase: Phase 1
A Phase I/II, Open-Label, Multi-Center Study Evaluating the Safety and Efficacy of Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
A Phase I/II, Open-Label, Multi-Center Study Evaluating the Safety and Efficacy of Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Procedure, Drug
Study Drugs: Liposomal Daunorubicin, Liposomal Cytarabine, Ruxolitinib
Study Phase: Phase 1/Phase 2
Phase II Study of Clinical Efficacy of Venetoclax in Combination With Azacitidine in Patients With Therapy Related Myelodysplastic Syndrome (t-MDS)
Phase II Study of Clinical Efficacy of Venetoclax in Combination With Azacitidine in Patients With Therapy Related Myelodysplastic Syndrome (t-MDS)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Other, Drug
Study Phase: Phase 2
A Pilot Study of Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
A Pilot Study of Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drug: Ivosidenib
Study Phase: Phase 2
A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination With Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia
A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination With Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cytarabine, Daunorubicin Hydrochloride, Gemtuzumab Ozogamicin, Midostaurin
Study Phase: Phase 1
Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drugs: Decitabine, PDR001, MBG453, Azacitidine
Study Phase: Phase 1
A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Drug
Study Drugs: ASTX660, ASTX727
Study Phase: Phase 1
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drugs: Alvocidib, Cytarabine
Study Phase: Phase 2
A Phase 1b/2 Study of TP-0903 in Patients With Acute Myeloid Leukemia and FLT3 Mutations
A Phase 1b/2 Study of TP-0903 in Patients With Acute Myeloid Leukemia and FLT3 Mutations
Enrollment Status: Completed
Publish Date: February 06, 2023
Intervention Type: Drug
Study Drugs: Azacitidine, Dubermatinib
Study Phase: Early Phase 1
View 9 Less Clinical Trials

71 Total Publications

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 12, 2025
Similar Doctors
Distinguished in Essential Thrombocythemia
Dr. Shyamal R. Bastola
Hematology Oncology | Hematology | Oncology
Distinguished in Essential Thrombocythemia
Dr. Shyamal R. Bastola
Hematology Oncology | Hematology | Oncology

Genesis Medical Group, LLC

2951 Maple Ave, 
Zanesville, OH 
 (53.1 miles away)
740-454-4000
Languages Spoken:
English, Nepalese
See accepted insurances
Accepting New Patients

Shyamal Bastola is a Hematologist Oncology specialist and a Hematologist in Zanesville, Ohio. Dr. Bastola is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC). Dr. Bastola is currently accepting new patients.

Advanced in Essential Thrombocythemia
Dr. Jennifer E. Vaughn
Hematology | Hematology Oncology
Advanced in Essential Thrombocythemia
Dr. Jennifer E. Vaughn
Hematology | Hematology Oncology

Osu Internal Medicine LLC

452 W 10th Ave, 
Columbus, OH 
 (0.1 miles away)
614-293-3737
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jennifer Vaughn is a Hematologist and a Hematologist Oncology provider in Columbus, Ohio. Dr. Vaughn is rated as an Advanced provider by MediFind in the treatment of Essential Thrombocythemia. Her top areas of expertise are Philadelphia-Negative Chronic Myeloid Leukemia, Polycythemia Vera, Essential Thrombocythemia, Acute Mountain Sickness, and Bone Marrow Aspiration. Dr. Vaughn is currently accepting new patients.

Advanced in Essential Thrombocythemia
Dr. Robert D. Rupert
Hematology Oncology | Hematology | Oncology
Advanced in Essential Thrombocythemia
Dr. Robert D. Rupert
Hematology Oncology | Hematology | Oncology

Union County Physician Corporation

388 Damascus Rd, Suite A, 
Marysville, OH 
 (25.8 miles away)
937-578-4040
Languages Spoken:
English, Arabic, Cantonese, French, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Rupert is a Hematologist Oncology specialist and a Hematologist in Marysville, Ohio. Dr. Rupert is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Adenoid Cystic Carcinoma, Laryngeal Cancer, Childhood Iron Deficiency Anemia, and Colorectal Cancer. Dr. Rupert is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Borate's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile